Ani Pharmaceuticals (ANIP) EBT Growth (3y) (2014 - 2026)
Ani Pharmaceuticals (ANIP) EBT Growth (3y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 21.00% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | -0.23% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 1.19% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 3.60% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -29.91% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 10.08% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 39.40% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Ani Pharmaceuticals | 1.58 Bn | 1.22 Bn | 165.89 Mn | 91.91% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.91% |
| Mar 31, 2026 | 164.85% |
| Dec 31, 2025 | 95.40% |
| Sep 30, 2025 | 68.28% |
| Jun 30, 2025 | 36.79% |
| Mar 31, 2025 | 40.47% |
| Dec 31, 2024 | 23.59% |
| Sep 30, 2024 | -64.31% |
| Jun 30, 2024 | 49.91% |
| Mar 31, 2024 | 593.38% |
| Dec 31, 2023 | 33.84% |
| Sep 30, 2023 | 467.45% |
| Jun 30, 2023 | 33.52% |
| Mar 31, 2023 | 30.44% |
| Dec 31, 2022 | 9.01% |
| Sep 30, 2022 | -71.99% |
| Jun 30, 2022 | -73.13% |
| Mar 31, 2022 | -211.46% |
| Dec 31, 2021 | -83.74% |
| Sep 30, 2021 | -46.05% |